Management of fibromyalgia

Current Psychiatry Reports

Volumn 5, Issue 3, 2003, Pages 218-224

  Patkar, Ashwin A ^a   Bilal, Louai ^b   Masand, Prakash S ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANALGESIC AGENT; ANTICONVULSIVE AGENT; CITALOPRAM; CLOMIPRAMINE; CYCLOBENZAPRINE; DOSULEPIN; FLUOXETINE; GABAPENTIN; HYPNOTIC AGENT; IBUPROFEN; LAMOTRIGINE; MAPROTILINE; NABUMETONE; NAPROXEN; NEFAZODONE; NORADRENALIN UPTAKE INHIBITOR; OPIATE; PARACETAMOL; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TIAGABINE; TOPIRAMATE; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE;

BEHAVIOR THERAPY; BODY WEIGHT DISORDER; CLINICAL TRIAL; COGNITIVE THERAPY; CONSTIPATION; DEPRESSION; DIZZINESS; FAMILY; FATIGUE; FIBROMYALGIA; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; HYPOTENSION; LIVER TOXICITY; LOW DRUG DOSE; MORNING STIFFNESS; NAUSEA; PAIN; PATIENT ATTITUDE; PHYSICIAN ATTITUDE; REVIEW; SEDATION; SEIZURE; SELF REPORT; SEXUAL DYSFUNCTION; SLEEP DISORDER; SOMNOLENCE; SYMPTOMATOLOGY; VISUAL IMPAIRMENT; VOMITING; WEIGHT GAIN; XEROSTOMIA;

EID: 3042670939     PISSN: 15233812     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11920-003-0046-9     Document Type: Review

References (62)

1. Wolfe F, Smythe HA, Yunus MB, et al.: The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report of the Multicenter Criteria Committee. Arthritis Rheum 1990, 33:160-172.
2. Lundberg G, Gerdle B: Tender point scores and their relations to signs of mobility symptoms, and disability in female home care personnel and the prevalence of fibromyalgia syndrome J Rheumatol 2002, 29:603-613.
3. Wolfe F, Ross K, Anderson J, et al.: The prevalence and characteristic of fibromyalgia in the general population. Arthritis Rheum 1995, 38:19-28.
4. Gilliland BC: Relapsing polychondritis and miscellaneous arthritides. In Harrison's Principle of Internal Medicine, edn 13. New York: McGraw Hill; 1994:1703-1710.
5. Silver DS, Wallace DJ: The management of fibromyalgia-associated syndromes. Rheum Dis Clin North Am 2002, 28:405-417.
6. McBeth J, Silman AJ: The role of psychiatric disorders in fibromyalgia. Curr Rheumatol Rep 2001, 3:157-164.
7. Schlenk EA, Erlen JA, Dunbar-Jacob J, et al.: Health-related quality of life in chronic disorders: a comparison across studies using the MOS SF-36. Qual Life Res 1998, 7:57-65.
8. Bendtsen L, Norregaard J, Jensen R, Olesen J: Evidence of qualitatively altered nociception in patients with fibromyalgia. Arthritis Rheum 1997, 40:98-102.
9. Bennett M: Emerging concepts in the neurobiology of chronic pain: evidence of abnormal sensory processing in fibromyalgia. Mayo Clin Proc 1999, 74:385-398.
10. Bennett R, Doubell TP, Mannion RJ, Woolf CJ: The dorsal horn: state dependent sensory processing, plasticity and the generation of pain. In Textbook of Pain. London: Churchill Livingstone; 2000:65-81.
11. Mountz JM, Bradley LA, Modell JG, et al.: Fibromyalgia in women: abnormalities of regional cerebral blood flow in the thalamus and the caudate nucleus are associated with low pain threshold levels. Arthritis Rheum 1995, 38:926-938.
12. Russell IJ, Orr MD, Littman B, et al.: Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum 1994, 37:1593-1601.
13. Russell IJ, Vaeroy H, Javors M, et al.: Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis Rheum 1992, 35:550-556.
14. Jones SL: Descending noradrenergic influences on pain. Prog Brain Res 1991, 88:381-394.
15. Moldofsky H, Scarisbrick P, England R, et al.: Musculoskeletal symptoms and non-REM sleep disturbances in patients with "fibrositis syndrome" and healthy subjects. Psychosom Med 1975, 37:341-351.
16. Moldofsky H, Scarisbrick P: Induction of neurasthenic musculoskeletal pain syndrome by selective sleep stage deprivation. Psychosom Med 1976, 38:35-44.
17. Dauvilliers Y, Touchon J: Sleep in fibromyalgia: review of clinical and polysomnographic data. Neurophysiol Clin 2001, 31:18-33.
18. Neeck G, Crofford LJ: Neuroendocrine perturbations in fibromyalgia and chronic fatigue syndrome. Rheum Dis Clin North Am 2000, 26:989-1002.
19. Heim C, Ehlert U, Hellhammer DH: The potential role of hypocortisolism in the pathophysiology of stress-related bodily disorders. In Psychoneuroendocrinology 2000, 25:1-35.
20. Robert M, Bennett, MD, Sharon C, et al.: A randomized, double-blind, placebo-controlled study of growth hormone in the treatment of fibromyalgia Am J Medicine 1998, 104:227-231.
21. Geenen R: Evaluation and management of endocrine dysfunction in fibromyalgia. Rheum Dis Clin North Am 2002, 28:389-394.
22. Burckhardt C: Nonpharmacologic management strategies in fibromyalgia. Rheum Dis Clin North Am 2002, 28:291-304.
23. Bennett R: The rational management of fibromyalgia patients. Rheum Dis Clin North Am 2002, 28:13-15.
24. Barkhuizen A: Rational and targeted pharmacologic treatment of fibromyalgia. Rheum Dis Clin North Am 2002, 28:261-290.
25. Goldenberg DL: Fibromyalgia syndrome a decade later: what have we learned? Arch Intern Med 1999, 159:777-785.
26. Arnold LM, Keck PE Jr, Welge JA: Antidepressant treatment of fibromyalgia: a meta-analysis and review. Psychosomatics 2000, 41:104-113.
27. O'Malley PG, Balden E, Tomkins G, et al.: Treatment of fibromyalgia with antidepressants: a meta-analysis. J Gen Intern Med 2000, 15:659-666.
28. Anderberg UM, Marteinsdottir I, von Knorring: Citalopram in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study. Eur J Pain 2000, 4:27-35.
29. Norregaard I, Volkmann H, Danneskiold-Samsoe B: A randomized controlled trial of citalopram in the treatment of fibromyalgia. Pain 1995, 61:445-449.
30. Arnold LM, Hess EV, Hudson JI, et al.: A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia. Am J Med 2002, 112:191-197.
31. Wolfe F, Cathey MA, Hawley DJ: A double-blind placebo controlled trial of fluoxetine in fibromyalgia. Scand J Rheumatol 1994, 23:255-259.
32. Goldenberg DL, Mayski M, Mossey C, et al.: A randomized double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis Rheum 1996, 39:1852-1859.
33. Giordano N, Geraci S: Efficacy and tolerability of paroxetine in patients with fibromyalgia syndrome: a single-blind study. Curr Ther Res 1999, 60:696-702.
34. Syuertsen JO, Smedsrud T, Lane RM: An open study of sertraline in fibromyalgia syndrome. Eur Neuropsychoparmacol 1995, 5:315-321.
35. Wetherhold EA, Carpenter DJ, Oakes R, et al.: A randomized, double-blind triple crossover study of the independent and combined efficacy of paroxetine and nabumetone in the treatment of fibromyalgia. Paper presented at the Annual Meeting of the American Psychiatric Association. New Orleans, LA, May 5-10, 2001.
36. Dwight MM, Arnold LM, O'Brien H, et al.: An open clinical trial of venlafaxine treatment of fibromyalgia. Psychosomatics 1998, 39:14-17.
37. Arnold LM: Antidepressants for fibromyalgia: latest word on the link to depression and anxiety. Curr Psychiatry 2002, 11:49-57.
38. Carette S, Mccain GA, Bell DA, et al.: Evaluation of amitriptyline in primary fibrositis: a double-blind, placebo-controlled study. Arthritis Rheum 1986, 29:655-659.
39. Caruso I, Puttinin PCS, Boccassinin L, et al.: Double-blind study of dothiepin versus placebo in the treatment of primary fibromyalgia syndrome. J Int Med Res 1987, 15:154-159.
40. Bennett RM, Gatter RA, Campbell SM, et al.: A comparison of cyclobenzaprine and placebo in the management of fibrositis. Arthritis Rheum 1988, 31:1535-1542.
41. Quimby LG, Gratwick GM, Whitney CD, et al.: A randomized trial of cyclobenzaprine for the treatment of fibromyalgia. J Rheumatol 1989, 16(suppl):140-143.
42. Carette S, Bell MJ, Reynolds WJ, et al.: Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia: a randomized, double-blind clinical trial. Arthritis Rheum 1994, 37:32-40.
43. Carette S, Oakson G, Guimont C, et al.: Sleep electroencephalography and the clinical response to amitriptyline. Arthritis Rheum 1995, 38:1211-1217.
44. Reynolds WJ, Moldofsky H, Saskin P, et al.: The effects of cyclobenzaprine on sleep physiology and symptoms in patients with fibromyalgia. J Rheumatol 1991, 18:452-454.
45. Bibolotti E, Borghi C, Pasculli E, et al.: The management of fibrositis: a double-blind comparison of maprotiline (Ludiomil), chlorimipramine, and placebo. J Clin Trials 1986, 23:269-280.
46. Wolfe F, Zhao S, Lane N: Preference for nonsteroidal anti-inflammatory drugs over acetaminophen by rheumatic disease patients: a survey of 1799 patients with osteoarthritis, rheumatoid arthritis, and fibromyalgia. Arthritis Rheum 2000, 43:378-385.
47. Serpell MG: Gabapentin in neuropathic pain syndromes: a randomized, double-blind, placebo-controlled trial. Pain 2002, 99:557-566.
48. Backonja MM: Use of anticonvulsants for treatment of neuropathic pain. Neurology 2002, 59(suppl):S14-S17.
49. Russell IJ, Fletcher EM, Michalek JE, et al.: Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam: a double-blind, placebo-controlled study. Arthritis Rheum 1991, 34:552-560.
50. Jacobsen S, Danneskiold-Samsoe B, Andersen RB: Oral S-adenosylmethionine in primary fibromyalgia: a double-blind clinical evaluation. Scand J Rheumatol 1991, 20:294-302.
51. Tavoni A, Vitali C, Bombardieri S, et al.: Evaluation of S-adenosylmethionine in primary fibromyalgia: a double-blind crossover study. Am J Med 1987, 83:107-110.
52. Tan EK, Ondo W: Restless legs syndrome: clinical features and treatment. Am J Med Sci 2000, 319:397-403.
53. Pachus WN: Modafinil may be a suitable treatment for the fatigue of fibromyalgia. Abstract presented at MYOPAIN: Fifth World Congress on Myofascial Pain and Fibromyalgia. Portland, OR, September 9-13, 2001.
54. Kiser RS, Cohen HM, Freedenfeld RN: Olanzapine for the treatment of fibromyalgia symptoms. J Pain Symptom Manage 2001, 22:704-708.
55. Bennett MI, Tai YM: Intravenous lignocaine in the management of primary fibromyalgia syndrome. Int J Clin Pharmacol Res 1995, 15:115-119.
56. Richards SC, Scott DL: Prescribed exercise in people with fibromyalgia: parallel group randomized controlled trial. BMJ 2002, 325:185-186.
57. Williams DA, Cary MA, Groner KH, et al.: Improving physical functional status in patients with fibromyalgia: a brief cognitive behavioral intervention. J Rheumatol 2002, 29:1280-1286.
58. Deluze C, Bosia L, Zirbs A, et al.: Electroacupuncture in fibromyalgia: results of a controlled trial. BMJ 1992, 305:1249-1252.
59. Haanen HC, Hoenderdos HT, van Romunde LK, et al.: Controlled trial of hypnotherapy in the treatment of refractory fibromyalgia. J Rheumatol 1991, 18:72-75.
60. Russell IJ: The promise of substance P inhibitors in fibromyalgia. Rheum Dis Clin North Am 2002, 28:329-342.
61. Spath M: Current experience with 5-HT3 receptor antagonists in fibromyalgia. Rheum Dis Clin North Am 2002, 28:319-328.
62. Farber L, Stratz TH, Bruckle W, et al.: Short-term treatment of primary fibromyalgia with the 5-HT3-receptor antagonist tropisetron: results of a randomized, double-blind, placebo-controlled multicenter trial in 418 patients. Int J Clin Pharmacol Res 2001, 21:1-13.